Anti-amyloid-β immunotherapy
1 paper studies it1 finding
Outcomes
1Alzheimer's disease progression
downin humans1
1 study
Alzheimer's disease progression
downin humans1
Anti-amyloid-β immunotherapy decreases alzheimer's disease progression in humans.
“Passive anti-amyloid-β immunotherapy has shifted from repeated phase 3 failure to reproducible, although modest, clinical slowing in biomarker-defined early Alzheimer's disease.”
Reviewbiomarker-defined early Alzheimer's disease
Amyloid-β Immunotherapy in Alzheimer's Disease: Challenges and Opportunities
Annual review of pathologyOct 16, 2026
Latest
1 paper in 12 monthsAnnual Review of Pathology
Amyloid-β Immunotherapy in Alzheimer's Disease: Challenges and Opportunities
ReviewAlzheimer's disease